May 21 – 23, 2024 | Boston, MA

Returning to Boston for its 6th year, the Treg-Directed Therapies Summit stands as the singular industry forum shining a spotlight on the groundbreaking research and clinical advancements in CAR-Treg and IL2 mutein therapies.

As the pioneering and longest-tenured meeting dedicated to optimizing and manipulating Treg-based approaches, this summit invites you to become part of a community at the forefront of innovation. Gain unparalleled insights into the latest developments driving specificity, delve into novel cell product design, and explore the engineering of CAR-Tregs to enhance cell stability and durability.

Don’t miss this unique opportunity to stay ahead in the dynamic landscape of Treg therapies. Join Beacon’s Immune Tolerance Research Analyst, Rachel Hourigan, for a look at the current Treg landscape for autoimmune diseases & recent deals and emerging companies, and contribute to the ongoing dialogue that shapes the future of cutting-edge medical advancements.